首页> 美国卫生研究院文献>Springer Open Choice >Efficacy Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

【2h】

Efficacy Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

机译：类风湿关节炎患者中多达两个疗程的利妥昔单抗生物仿制药CT-P10与创新药物利妥昔单抗的疗效安全性和药代动力学：截至第一阶段随机对照试验第72周的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

BackgroundCT-P10 is a biosimilar of innovator rituximab (RTX), a biological therapy used to treat patients with rheumatoid arthritis (RA) who have responded inadequately to anti-tumor necrosis factor agents.

机译：背景技术CT-P10是利妥昔单抗（RTX）的生物仿制药，该药物是用于治疗对抗肿瘤坏死因子药物反应不足的类风湿关节炎（RA）患者的生物疗法。

著录项

期刊名称 Springer Open Choice
作者
Dae Hyun Yoo; Chang-Hee Suh; Seung Cheol Shim; Slawomir Jeka; Francisco Fidencio Cons Molina; Pawel Hrycaj; Piotr Wiland; Eun Young Lee; Francisco G. Medina-Rodriguez; Pavel Shesternya; Sebastiao Radominski; Marina Stanislav; Volodymyr Kovalenko; Dong Hyuk Sheen; Leysan Myasoutova; Mie Jin Lim; Jung-Yoon Choe; Sang Joon Lee; Sung Young Lee; Sung Hwan Kim; Won Park;
展开▼
作者单位

展开▼
年(卷),期 -1(31),4
年度 -1
页码 357–367
总页数 11
原文格式 PDF
正文语种
中图分类外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial [J] . Yoo Dae Hyun, Suh Chang-Hee, Shim Seung Cheol, BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2017,第4期

机译：高达两种疗程的疗效，安全性和药代动力学在类风湿性关节炎患者中患者的毒素蛋白生物仿生CT-P10与Innovator Rituximab的疗效，安全性和创新者Rituximab：结果最多为一期随机对照试验的第72周
2. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial [J] . Suh Chang-Hee, Yoo Dae Hyun, Berrocal Kasay Alfredo, BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2019,第1期

机译：生物仿制性CT-P10的长期疗效和安全性与风湿性关节炎中的创新者Rituximab：随机期III试验的48周结果
3. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial [J] . Shim Seung Cheol, Bozic-Majstorovic Ljubinka, Kasay Alfredo Berrocal, Rheumatology . 2019,第12期

机译：从Rituximab切换到类风湿性关节炎中的生物仿制性CT-P10的功效和安全性：随机阶段3试验中的72周数据
4. Impact of Complementary Therapies via Mobile Technologies on Icelandic Same Day Surgical Patients' Reports of Anxiety, Pain and Self-Efficacy in Healing: A Randomized Controlled Trial in Process [C] . Margaret M. Hansen MEDINFO . 2013

机译：互补疗法通过移动技术对冰岛同日外科患者的影响焦虑，痛苦和自我疗效愈合中的报告：过程中的随机对照试验
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial [O] . Chang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, -1

机译：类风湿关节炎中生物仿制药CT-P10与创新药利妥昔单抗的长期疗效和安全性：来自随机III期试验的48周结果
7. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial [O] . Seung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay, 2019

机译：从Rituximab切换到类风湿性关节炎中的生物仿制性CT-P10的功效和安全性：随机阶段3试验中的72周数据

Efficacy Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅